The placebo-controlled trial, which enrolled 42 subjects, evaluated whether NM504 administered for four weeks could improve the glucose tolerance of subjects with prediabetes and untreated type 2 diabetes
The Phase II trial met its primary safety endpoint and achieved statistically significant improvement in a measure of executive function (cognition), which included part of the trial’s main
The trial supplements the EINSTEIN Trial Programme, which established in the EINSTEIN Extension study that rivaroxaban 20mg once daily reduces the risk of long-term prevention of recurrent symptomatic
The deal covers the development and potentially the commercialization of Cellectis’ lead product candidate, UCART19, as well as the research, development, and commercialization of five other product candidates
With the acquisition, DKSH continues its strategic expansion in the industry by adding a direct presence in Macau to its pan-Asian coverage. With the move, DKSH is driving
Financial terms of the transaction are not disclosed. CoStim was founded in 2012 by MPM Capital managing director Luke Evnin together with MPM Capital operations managing director Robert
In addition, Horizon’s customers can now access Sirion’s off-the-shelf validated shRNA and cDNA over-expression reagents. Through the deal, Horizon will now offer a broad spectrum of gene modulation
A total of 45 patients with mild to moderate ulcerative colitis are enrolled in the trial, which is designed to assess the safety, efficacy, pharmacokinetics and effects on
In 2011, the companies have signed a worldwide agreement to develop and market tivozanib outside of Asia for the treatment of a broad range of cancers As part
Under the deal, Moberg Pharma has been granted Menarini Asia-Pacific the exclusive rights to market and sell Kerasal Nail in eight Southeast Asian countries. The deal builds on
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.